title: Should adjuvant weekly paclitaxel be considered less efficacious than anthracyclines plus cyclophosphamide for lower-risk patients with early-stage breast cancer?
authors.affiliation: University of Brescia at Spedali Civili Hospital, Brescia, Italy vitoamoroso@alice.it.
authors.forename: Vito
authors.initials: V
authors.lastname: Amoroso
authors.affiliation: Spedali Civili Hospital, Brescia, Italy.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Pedersini
authors.affiliation: Barts and The London School of Medicine and Dentistry, London, United Kingdom.
authors.forename: Phoebe
authors.initials: P
authors.lastname: Sharratt
authors.affiliation: Spedali Civili Hospital, Brescia, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Vassalli
authors.affiliation: University of Brescia at Spedali Civili Hospital, Brescia, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Ferrari
authors.affiliation: University of Brescia, Brescia, Italy.
authors.forename: Sandra
authors.initials: S
authors.lastname: Sigala
authors.affiliation: Spedali Civili Hospital, Brescia, Italy.
authors.forename: Edda
authors.initials: E
authors.lastname: Simoncini
authors.affiliation: University of Brescia at Spedali Civili Hospital, Brescia, Italy.
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*
chemical_list: D017239:Paclitaxel